title: Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
abstract: Nebivolol, a vasodilatory β1-blocker, may be well suited for the hemodynamics of the younger hypertensive patient. In this 8-week trial, 18- to 54-year-olds with a diastolic blood pressure (DBP) of 95 mm Hg to 109 mm Hg who completed a 4-week placebo-only phase were randomized to receive nebivolol (5 mg/d, titrated to 10-20 mg/d based on achievement of blood pressure <140/90 mm Hg [n=427]) or placebo (n=214). Primary and secondary efficacy parameters were changes in trough seated DBP and systolic blood pressure (SBP), respectively. Safety parameters included adverse events (AEs). The baseline mean age was 45.3 years; SBP/DBP, 154/100 mm Hg; and heart rate, 78 beats per minute. Completion rates were 91.3% (nebivolol) and 88.3% (placebo). At endpoint, there was a significant effect of nebivolol over placebo for DBP (-11.8 mm Hg vs -5.5 mm Hg, P<.001) and SBP (-13.7 mm Hg vs -5.5 mm Hg, P<.001). Total AE rates were 34.7% (nebivolol) and 32.2% (placebo). Nebivolol monotherapy is efficacious and well tolerated in adults younger than 55 years of age with increased DBP.
authors.affiliation: Tulane University, New Orleans, LA.
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Giles
authors.forename: Bobby V
authors.initials: BV
authors.lastname: Khan
authors.forename: June
authors.initials: J
authors.lastname: Lato
authors.forename: Lillian
authors.initials: L
authors.lastname: Brener
authors.forename: Yimin
authors.initials: Y
authors.lastname: Ma
authors.forename: Tatjana
authors.initials: T
authors.lastname: Lukic
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000367:Age Factors; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001578:Benzopyrans / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004311:Double-Blind Method; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol
references.citation: Clin Nephrol. 1992;38 Suppl 1:S78-86
references.pmid: 1363538
references.citation: Circulation. 2001 Dec 4;104(23):2815-9
references.pmid: 11733400
references.citation: Ther Adv Cardiovasc Dis. 2012 Oct;6(5):185-99
references.pmid: 23008339
references.citation: Am J Hypertens. 1988 Jul;1(3 Pt 1):309-12
references.pmid: 3291897
references.citation: Clin Ther. 1999 Jun;21(6):1074-90; discussion 1073
references.pmid: 10440628
references.citation: J Am Coll Cardiol. 1996 Feb;27(2):277-84
references.pmid: 8557894
references.citation: Eur J Pharmacol. 2003 Jan 26;460(1):19-26
references.pmid: 12535855
references.citation: BMJ. 2008 May 17;336(7653):1121-3
references.pmid: 18480116
references.citation: JAMA. 2003 Nov 5;290(17):2271-6
references.pmid: 14600185
references.citation: Ann Intern Med. 2008 Jul 15;149(2):91-9
references.pmid: 18626048
references.citation: N Engl J Med. 1998 Jun 4;338(23):1650-6
references.pmid: 9614255
references.citation: J Clin Hypertens (Greenwich). 2007 Sep;9(9):667-76
references.pmid: 17786067
references.citation: J Clin Hypertens (Greenwich). 2007 Nov;9(11):866-75
references.pmid: 17978594
references.citation: Am J Hypertens. 1995 Mar;8(3):311-5
references.pmid: 7794581
references.citation: Clin Ther. 2011 Sep;33(9):1150-61
references.pmid: 21864908
references.citation: Curr Med Res Opin. 2010 Mar;26(3):615-29
references.pmid: 20067434
references.citation: J Am Coll Cardiol. 2012 Jun 12;59(24):2206-16
references.pmid: 22676942
references.citation: Clin Pharmacol Ther. 1989 Aug;46(2):169-76
references.pmid: 2667837
references.citation: Am J Hypertens. 1999 Feb;12(2 Pt 2):50S-55S
references.pmid: 10090295
references.citation: JAMA. 2002 Jan 16;287(3):356-9
references.pmid: 11790215
references.citation: J Am Coll Cardiol. 2011 Nov 29;58(23):2396-403
references.pmid: 22115646
references.citation: Hypertension. 2010 Nov;56(5):824-30
references.pmid: 20921430
references.citation: Arch Intern Med. 2002 Mar 11;162(5):610-1
references.pmid: 11871936
references.citation: Hypertension. 2006 Sep;48(3):424-30
references.pmid: 16880344
references.citation: JAMA. 2010 May 26;303(20):2043-50
references.pmid: 20501926
references.citation: J Hypertens. 2008 Jul;26(7):1313-20
references.pmid: 18551005
references.citation: Arch Intern Med. 2001 Jun 25;161(12):1501-8
references.pmid: 11427097
references.citation: J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9
references.pmid: 19815121
references.citation: Circulation. 2001 Mar 6;103(9):1245-9
references.pmid: 11238268
references.citation: Blood Press Monit. 1996 Jun;1(3):283-288
references.pmid: 10226245
references.citation: Am J Cardiol. 1988 Jan 1;61(1):117-21
references.pmid: 3276117
references.citation: Lancet. 1983 Oct 29;2(8357):983-6
references.pmid: 6138591
references.citation: Clin Cardiol. 2010 Apr;33(4):E20-7
references.pmid: 20162736
references.citation: Am J Hypertens. 1996 Nov;9(11):113S-120S
references.pmid: 8931844
references.citation: Circulation. 2007 Jan 16;115(2):221-7
references.pmid: 17210838
references.citation: J Cardiovasc Pharmacol. 2010 Sep;56(3):275-81
references.pmid: 20571428